Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases

NCT03497767 is registered in ClinicalTrials.gov with Trans Tasman Radiation Oncology Group as lead sponsor.

NCT NCT03497767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03497767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomised Phase II Trial of Osimertinib With or Without Stereotactic Radiosurgery for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases
Lead sponsor
Trans Tasman Radiation Oncology Group
Phase
Phase 2
Overall status
Completed
Start date
August 15, 2019
Completion date
April 30, 2024
Enrollment
40 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic non small cell lung cancer